The effects of fast walking on persons with sarcopenia
10.3760/cma.j.issn.0254-1424.2023.08.009
- VernacularTitle:快走运动对肌肉减少症患者步行能力和握力以及血清GDF-8和IGF-1的影响
- Author:
Haiying HUANG
1
;
Ping LIN
;
Qin WANG
;
Qian REN
;
Kanglu GAO
;
Chengcheng KONG
;
Fangyuan WANG
Author Information
1. 杭州市第三人民医院老年医学科，杭州 310009
- Keywords:
Walking;
Sarcopenia;
Walking speed;
Serum factors
- From:
Chinese Journal of Physical Medicine and Rehabilitation
2023;45(8):715-719
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe any effect of fast walking on walking speed, 6-minute walking test (6MWT) time, and on serum levels of growth differentiation factor-8 (GDF-8) and insulin-like growth factor-1 (IGF-1) in patients with sarcopenia.Methods:A total of 61 sarcopenia patients were randomly divided into an observation group ( n=31) and a control group ( n=30). Both groups were given conventional drug therapy. In addition, the observation group underwent 30-minutes of walking at 100-120 steps/min (about 60% of maximum heart rate) three times a week for 12 weeks. The control group also walked, but at 70-90 steps/min (less than 50% of maximum heart rate). Grip strength, walking speed, 6MWT time, skeletal muscle index (ASMI) and serum GDF-8 and IGF-1 were compared before and after the intervention. Results:There were no significant differences in grip strength or ASMI between observation group and control group (comparing males with males and females with females) before the experiment. Afterward, grip strength and ASMI in the observation group had increased significantly on average. Both were then significantly higher than the control groups′ averages, which had not changed significantly. Average walking speed, 6MWT time and serum IGF-1 levels had improved significantly in both groups, but the observation group′s average improvement was significantly greater. A significant decrease the average serum GDF-8 level was observed in the observation group, but not in the control group.Conclusion:Fast walking can improve the walking of persons with sarcopenia, raise serum IGF-1 levels, and significantly reduce serum GDF-8.
